Company Profile

AUROBINDO PHARMA LTD.

NSE : AUROPHARMABSE : 524804ISIN CODE : INE406A01037Industry : Pharmaceuticals & DrugsHouse : Aurobindo
BSE902.65-27.25 (-2.93 % )
PREV CLOSE (Rs.) 929.90
OPEN PRICE (Rs.) 930.15
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 56317
TODAY'S LOW / HIGH (Rs.)897.80 937.95
52 WK LOW / HIGH (Rs.)281.15 996.65
NSE902.25 -27.75 (-2.98 % )
PREV CLOSE(Rs.) 930.00
OPEN PRICE (Rs.) 935.00
BID PRICE (QTY) 902.25 (99 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 2019465
TODAY'S LOW / HIGH(Rs.) 897.50 938.00
52 WK LOW / HIGH (Rs.)288.85 996.85

Company News

Date Heading Details
24-Dec-2020 Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised) We enclose a copy of the Press Release that is being issued by the Company in connection with signing an exclusive agreement between the Company and COVAXX to develop and commercialize COVID-19 Vaccine UB-612 for India and UNICEF.
24-Dec-2020 Aurobindo Pharma enters into exclusive license agreement with COVAXX <p align="justify">Aurobindo Pharma has entered into an Exclusive License Agreement with COVAXX, a US-based company, to develop, commercialize and manufacture UB-612, the first Multitope Peptide-based Vaccine to fight COVID-19, for India and the United Nations Children's Fund (UNICEF) agency. COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate.</p><p align="justify">Under the signed agreement, Aurobindo has obtained the exclusive rights to develop, manufacture and sell COVAXX's UB-612 vaccine in India and to UNICEF, as well as non-exclusive rights in other select emerging and developing markets. Aurobindo and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXX's vaccine candidate, UB-612. Aurobindo will manufacture the finished doses at its facilities in Hyderabad. Aurobindo has the capacity of manufacturing 220 million doses in multi-dose presentation and is building additional facilities to have a total capacity of nearly 480 million doses by June 2021.</p><p align="justify">Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.<br></p>
24-Dec-2020 Aurobindo Pharma gains on entering into exclusive license agreement with COVAXX <p align="justify">Aurobindo Pharma is currently trading at Rs. 897.95, up by 8.05 points or 0.90% from its previous closing of Rs. 889.90 on the BSE.</p><p align="justify">The scrip opened at Rs. 900.00 and has touched a high and low of Rs. 910.00 and Rs. 900.00 respectively. </p><p align="justify">The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 967.60 on 10-Aug-2020 and a 52 week low of Rs. 281.15 on 23-Mar-2020.</p><p align="justify">Last one week high and low of the scrip stood at Rs. 910.00 and Rs. 801.00 respectively. The current market cap of the company is Rs. 52142.68 crore.</p><p align="justify">The promoters holding in the company stood at 52.01%, while Institutions and Non-Institutions held 36.68% and 11.31% respectively.</p><p align="justify">Aurobindo Pharma has entered into an Exclusive License Agreement with COVAXX, a US-based company, to develop, commercialize and manufacture UB-612, the first Multitope Peptide-based Vaccine to fight COVID-19, for India and the United Nations Children's Fund (UNICEF) agency. COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate.</p><p align="justify">Under the signed agreement, Aurobindo has obtained the exclusive rights to develop, manufacture and sell COVAXX's UB-612 vaccine in India and to UNICEF, as well as non-exclusive rights in other select emerging and developing markets. Aurobindo and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXX's vaccine candidate, UB-612. Aurobindo will manufacture the finished doses at its facilities in Hyderabad. Aurobindo has the capacity of manufacturing 220 million doses in multi-dose presentation and is building additional facilities to have a total capacity of nearly 480 million doses by June 2021.</p><p align="justify">Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.<br></p>
24-Dec-2020 Aurobindo Pharma, Tata Communications and ARSS Infrastructure Projects to see some action today <p align="justify"><strong>Aurobindo Pharma</strong> has entered into an Exclusive License Agreement with COVAXX, a US-based company, to develop, commercialize and manufacture UB-612, the first Multitope Peptide-based Vaccine to fight COVID-19, for India and the United Nations Children's Fund (UNICEF) agency. COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate. Under the signed agreement, Aurobindo has obtained the exclusive rights to develop, manufacture and sell COVAXX's UB-612 vaccine in India and to UNICEF, as well as non-exclusive rights in other select emerging and developing markets.</p><p align="justify"><strong>Tata Communications</strong> has acquired majority equity stake of 58.1% in Oasis Smart SIM Europe SAS (Oasis), a France-headquartered embedded-SIM (eSIM) technology provider. Oasis develops and provides advanced technologies and personalized services to enable the deployment of eSIM and SIM technologies. With this investment, eSIM technology will be fully integrated into Tata Communications MOVE, enabling an end-to-end embedded connectivity solution and strengthening Tata Communications MOVE as a single source platform for global enterprise mobility needs. </p><p align="justify"><strong>ARSS Infrastructure Projects</strong> has received a work order of Rs 301.20 crore only for execution of work of 4 Laning of Itanagar to Banderdewa section of NH-415 from 51+700 to km 59-199 (Packape-C) on FPC mode in the state of Arunachal Pradesh. The order has been awarded in favour of the company by Office of Chief Engineer (Zone-V(I)) Director General (RD &amp; Special Secretary, Government of India, Ministry of Roads Transport &amp; Highways, New Delhi. </p><p align="justify"><strong>ACC</strong> has received an approval for the renewal of the existing Technology and Know-How Agreement (TKH Agreement) with Holcim Technology (HTL) under which the company pays TKH fees at 1% of net sales each year, to HTL, for a period of 2 years with effect from January 01, 2021, i.e., on the same terms of the existing TKH Agreement. The Board of Directors of the company at its meeting held on December 23, 2020, has approved the same. </p><p align="justify"><strong>Kirloskar Ferrous Industries</strong> has completed the acquisition of movable and immovable assets relating to the pig iron plant of VSL Steels (the Seller) situated at Paramenahally Village, Hiriyur, Chitradurga District, Karnataka. The company is in process to renovate those assets and to obtain necessary approvals / permissions / licenses from statutory / government authorities for commencement of operations. </p><p align="justify"><strong>Kings Infra Ventures</strong> has raised Rs 26 lakh through Unlisted Secured Redeemable Non- Convertible Debentures (NCDs) and allotted Seventh tranche of 2600 NCDs having face value of Rs 1000 each on Private Placement. The Debenture Committee of the company at its meeting held on December 22, 2020, has allotted the same.&nbsp; </p><p align="justify"><strong>Maruti Suzuki India</strong> has completed a housing township of affordable modern eco-friendly houses for its employees in Dharuhera and handed over the first batch of houses to its employees. The remaining apartments out of a total of 360 are expected to be ready for possession in a staggered manner. One of the key reasons of Maruti Suzuki's sustained success and leadership despite presence of many global players is that the relationship between the company and its employees is of partnership and mutual trust.<br></p>
11-Dec-2020 Announcement under Regulation 30 (LODR)-Press Release / Media Release We enclose a copy of the Press Release that is being issued by the Company in connection with USFDA approval received by the Company for Dexmedetomidine HCL in 0.9% Sodium Chloride Injection.
10-Dec-2020 Aurobindo Pharma surges on getting USFDA's nod for Dexmedetomidine HCL in 0.9% Sodium Chloride Injection <p align="justify">Aurobindo Pharma is currently trading at Rs. 894.80, up by 7.10 points or 0.80% from its previous closing of Rs. 887.70 on the BSE.<br></p><p align="justify">The scrip opened at Rs. 894.10 and has touched a high and low of Rs. 907.95 and Rs. 888.85 respectively. So far 65541 shares were traded on the counter.<br></p><p align="justify">The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 967.60 on 10-Aug-2020 and a 52 week low of Rs. 281.15 on 23-Mar-2020.<br></p><p align="justify">Last one week high and low of the scrip stood at Rs. 923.00 and Rs. 885.15 respectively. The current market cap of the company is Rs. 52365.33 crore.<br></p><p align="justify">The promoters holding in the company stood at 52.01%, while Institutions and Non-Institutions held 36.68% and 11.31% respectively.<br></p><p align="justify">Aurobindo Pharma has received final approval from the US Food &amp; Drug Administration (USFDA) to manufacture and market Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, 200 mg/50 mL and 400 mg/100 mL Single Dose flexible containers (Bags). The company's Dexmedetomidine HCI in 0.9% Sodium Chloride Injection is a therapeutic equivalent generic version of Hospira's Precedex in 0.9% Sodium Chloride Injection. The product will be launched in January 2021.</p><p align="justify">This is the 79th ANDA to be approved out of Unit IV formulation facility in Hyderabad, India used for manufacturing injectable &amp; ophthalmic products. The company now has a total of 459 ANDA approvals (431 Final approvals and 28 tentative approvals) from USFDA.</p><p align="justify">Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.<br></p>
09-Dec-2020 Aurobindo Pharma gets USFDA's nod for Dexmedetomidine HCL in 0.9% Sodium Chloride Injection <p align="justify">Aurobindo Pharma has received final approval from the US Food &amp; Drug Administration (USFDA) to manufacture and market Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, 200 mg/50 mL and 400 mg/100 mL Single Dose flexible containers (Bags). The company's Dexmedetomidine HCI in 0.9% Sodium Chloride Injection is a therapeutic equivalent generic version of Hospira's Precedex in 0.9% Sodium Chloride Injection. The product will be launched in January 2021. </p><p align="justify">This is the 79th ANDA to be approved out of Unit IV formulation facility in Hyderabad, India used for manufacturing injectable &amp; ophthalmic products. The company now has a total of 459 ANDA approvals (431 Final approvals and 28 tentative approvals) from USFDA.</p><p align="justify">Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.<br></p>
09-Dec-2020 Aurobindo Pharma informs about press release <p align="justify">Aurobindo Pharma has informed that it has enclosed a copy of the Press Release on 9th December 2020 that is being issued by the Company in connection with USFDA approval received by the Company for Dexmedetomidine HCL in 0.9% Sodium Chloride Injection.</p><p align="justify">The above information is a part of company's filings submitted to BSE.<br></p>
01-Dec-2020 Aurobindo Pharma's arms ink pact with affiliate of New Mountain Capital LLC, NY, Jarrow Formulas Inc <p align="justify">Aurobindo Pharma's wholly owned subsidiary -- Aurobindo Pharma USA, Inc. and Natrol LLC, USA, a wholly owned step -down subsidiary of the Company, have entered into a definitive agreement with an affiliate of New Mountain Capital LLC, NY and Jarrow Formulas Inc., to dispose of Natrol LLC, USA, including its business assets as a going concern with related assets, liabilities, products, brands and employees.</p><p align="justify">Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.<br></p>
01-Dec-2020 Aurobindo Pharma jumps after its arms ink pact with affiliate of New Mountain Capital LLC, NY, Jarrow Formulas Inc <P align=justify>Aurobindo Pharma is currently trading at Rs. 891.15, up by 23.10 points or 2.66% from its previous closing of Rs. 868.05 on the BSE.<BR><P align=justify>The scrip opened at Rs. 870.00 and has touched a high and low of Rs. 896.60 and Rs. 870.00 respectively. So far 73461 shares were traded on the counter.<BR><P align=justify>The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 967.60 on 10-Aug-2020 and a 52 week low of Rs. 281.15 on 23-Mar-2020.<BR><P align=justify>Last one week high and low of the scrip stood at Rs. 896.60 and Rs. 834.95 respectively. The current market cap of the company is Rs. 52116.31 crore.<BR><P align=justify>The promoters holding in the company stood at 52.01%, while Institutions and Non-Institutions held 36.68% and 11.31% respectively.<BR><P align=justify>Aurobindo Pharma's wholly owned subsidiary -- Aurobindo Pharma USA, Inc. and Natrol LLC, USA, a wholly owned step -down subsidiary of the Company, have entered into a definitive agreement with an affiliate of New Mountain Capital LLC, NY and Jarrow Formulas Inc., to dispose of Natrol LLC, USA, including its business assets as a going concern with related assets, liabilities, products, brands and employees.<P align=justify>Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.<BR>